Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutetium Lu 177 Dotatate vs Capecitabine and Temozolomide in Pancreatic Neuroendocrine Tumors
NCT05247905Phase 2Active, not recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Feb 2023
- Primary completion
- Oct 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium Lu 177 dotatate in Pancreatic neuroendocrine tumor (PanNET), sponsored by Cancer and Leukemia Group B. Started Feb 2023; status: active, not recruiting.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT05247905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05247905.